Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs Meto

Embody
Graded #52

Higher grade

vs+14.5
Meto
Graded #278

Lower grade

The verdict

Embody takes it — 76.5/100 to 62/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbody +43
88
45
Dose & formulationEmbody +43
83
40
Clinical oversightMeto +5
83
88
Labs & monitoringMeto +31
54
85
FulfillmentEmbody +26
93
67
Contract termsMeto +30
25
55
Embody · left barMeto · right bar

The numbers

MetricEmbodyMeto
WeighScore76.5/10062/100
GradeCC
Scorecard rank#52#278
Semaglutide$79/mo (all doses, promotional rate, compounded)Not disclosed
Tirzepatide$129/mo (all doses, promotional rate, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Meto

Graded #278 · C

Strengths

  • Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
  • Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
  • Matches patients with endocrinologists and obesity medicine specialists within minutes
  • Offers compounded semaglutide and tirzepatide with board-certified physician oversight
  • Handles all prior-auth paperwork; provider location pages exist for all 50 US states

Where it loses points

  • Medication pricing fully gated behind quiz — no public cash price for sema or tirz
  • Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
  • No LegitScript certification or named compounding pharmacy found on any public page
  • Company leadership and clinical team not disclosed publicly
  • Self-pay cash pricing exists per site copy but is not published anywhere

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard